Navigation Links
Multipotent Cell-Secreted Extracellular Matrix Supports Cartilage Formation

Chicago, IL (PRWEB) May 08, 2015

Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, will present new research on its human extracellular matrix (hECM) material in the promotion of cartilage regeneration during the International Cartilage Repair Society (ICRS) 2015 Meeting, taking place May 8-11, 2015 in Chicago, IL. The orthobiologic applications of all of Histogen’s products are being developed by its worldwide joint venture, PUR Biologics LLC.

Histogen has previously shown that hypoxia-induced multipotent cells produce soluble and insoluble materials that contain components associated with stem cell niches in the body and with scarless healing. These proteins include a variety of laminins, osteonectin, decorin, hyaluronic acid, collagen type IV, SPARC, CXCL12, NID1, NID2, NOTCH2, tenascin, thrombospondin, fibronectin, versican, and fibrillin-2. In vitro studies further demonstrated that the CCM and ECM promote the adhesion, proliferation and migration of bone marrow-derived human mesenchymal stem cells (MSCs).

In this latest research, in vivo studies with the hECM were undertaken to determine their potential as orthobiologics. Rabbit studies demonstrated the potential of the hECM to promote regeneration and repair of full-thickness articular cartilage defects. Eight weeks following hECM treatment of femoral osteochondral defects, mature bone and hyaline cartilage formation was seen, exemplified by the presence of a tide mark and integration into the adjacent cartilage. This work is currently being repeated in a goat cartilage defect model, with similar results to date.

“The efficacy we have seen with the multipotent cell-secreted ECM in bone and cartilage regeneration is unprecedented,” said Ryan Fernan, CEO of PUR Biologics. “The preclinical work overwhelmingly supports use of the material as an orthobiologic to reduce inflammation and promote cartilage regeneration in the articulating joint and intervertebral spinal disc. We look forward to entering human trials for these indications, as well as to continuing our research on utilizing the product for soft tissue repair in a variety of sports injuries.”

Histogen’s cell conditioned media (CCM) and hECM were also evaluated in an ex vivo rabbit intervertebral spinal disc model to study the effects of these materials in an environment where an extensive inflammatory response was induced by thrombin injection. Compared to untreated controls, both the CCM and ECM treatment significantly down regulated the expression of the inflammatory cytokine genes IL-1, IL-6, TNF-alpha, as well as the genes encoding the extracellular matrix degrading enzymes MMP3, and ADAMTS4, while upregulating aggrecan expression in the annulus fibrosus and nucleus pulposus tissue.

Dr. Gail Naughton, CEO of Histogen, will present “Human Cell Conditioned Media and Extracellular Matrix Reduce Inflammation and Support Hyaline Cartilage Formation” at the ICRS 2015 meeting in Chicago on May 9, 2015. Following the event, the presentation will be available upon request.

About PUR Biologics
PUR Biologics is dedicated to providing regenerative biologic solutions to address musculoskeletal surgical needs, including spine, dental, ligament and medical device coating applications. In addition to distribution of approved allograft and biologic products, PUR is focused on development of next-generation orthopedic products based upon human protein and growth factor materials for bone and tissue regeneration. For more information visit

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen’s Method of Generating Multipotent Stem Cells Receives US Patent
2. Multipotent Stem Cell Proteins Support Rejuvenation While Inhibiting Skin Cancer
3. Multipotent Stem Cell Proteins Support Soft Tissue Regeneration
4. Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
5. Unique Extracellular Matrix Used in Patient Successfully Treated for Flesh Eating Bacteria
6. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
7. 3D Biomatrix Technology Recognized by NC3Rs 3Rs Prize
8. BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment
9. LC/MS Biomarker Assay Validation Strategies Using Surrogate Matrix and Surrogate Analyte Approaches, New Life Science Webinar Hosted by Xtalks
10. Applied Silicone Launches Silicone Gel System with Dual Matrix Technology
11. CombiMatrix Selects Cryoport as Logistics Partner for the Distribution of Its New Genetic Screening Service
Post Your Comments:
(Date:6/18/2019)... ... 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived ... for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The ... This IND is the first of several planned clinical trials which will enable ...
(Date:6/11/2019)... MONTREAL (PRWEB) , ... June 10, 2019 , ... ... growth of its distribution network with the appointment of Biofeedback Tech Ltd ... physiological monitoring systems are an essential part of many therapeutic treatments and clinical ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed journals. ... continually expanding library of more than 20 million articles, sourced from more than ...
(Date:6/11/2019)... ... June 11, 2019 , ... Veterinary Regenerative Medicine ... (PSC) , has announced that their GMP facility for cell production is now ... manufacturing. This is an important milestone for VetStem as it expands into ...
Breaking Biology Technology:
(Date:6/14/2019)... ... , ... Molecular diagnostics segment is the fastest-growing segment within the global IVD ... segments that are expected to drive the growth are infectious diseases, cancer, and transplant ... Kalorama’s The World Molecular Diagnostics Market, 8th Edition . , The discovery of ...
(Date:6/11/2019)... ... June 12, 2019 , ... With a rapidly growing customer ... the Geneious Biologics platform as a premium hub for bioinformatics and computer programming ... “The Geneious team has done an excellent job accommodating our specific data, resulting ...
(Date:6/6/2019)... (PRWEB) , ... June 05, 2019 , ... ... announces the opening of a new network station and service center in Mexico ... and 12th in the world — with more than $1.75 billion in pharmaceutical ...
Breaking Biology News(10 mins):